|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-2-1
|
|
pubmed:abstractText |
The results of four randomized international multicentric trials evaluating the therapeutic benefit of Herceptin in the adjuvant treatment of HER2-neu positive primary breast cancer have been reported. These reports showed that even after short term follow up one year of Herceptin resulted in improved disease free, metastases free and overall survival. Design and results of these four studies and the recommendations of national and international societies for the use of Herceptin in the adjuvant setting will be discussed.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0044-4197
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
30-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16450285-Antibodies, Monoclonal,
pubmed-meshheading:16450285-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16450285-Antineoplastic Agents,
pubmed-meshheading:16450285-Breast Neoplasms,
pubmed-meshheading:16450285-Chemotherapy, Adjuvant,
pubmed-meshheading:16450285-Disease-Free Survival,
pubmed-meshheading:16450285-Female,
pubmed-meshheading:16450285-Follow-Up Studies,
pubmed-meshheading:16450285-Germany,
pubmed-meshheading:16450285-Humans,
pubmed-meshheading:16450285-Multicenter Studies as Topic,
pubmed-meshheading:16450285-Neoplasm Staging,
pubmed-meshheading:16450285-Randomized Controlled Trials as Topic
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
|
|
pubmed:affiliation |
Univ.-Frauenklinik Tübingen. Jens.Huober@med.uni-tuebingen.de
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
